-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Teicoplanin Phosphate for Injection (200mg) Has Been Approved.
Category:
Time：2023-05-30
On May 30, the chemical drug of Class 4—Tazobactam Phosphate Injection (200mg)—submitted by Shijiazhuang No.4 Pharmaceutical Group received the Drug Production Registration Approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This is the group’s 28th new product approved this year.
On May 30, the chemical drug injection of Telavancin Phosphate (200mg), Class 4, submitted by Shijiazhuang No.4 Pharmaceutical Group, received the Drug Production Registration Approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This is the group’s 28th new product approved this year.
It is reported that the newly approved injectable tedizolid phosphate is a lyophilized powder for injection, primarily used for the treatment of acute bacterial skin and skin-structure infections (ABSSSI).
Previously, the group’s application for the active pharmaceutical ingredient tedizolid phosphate was approved by the National Medical Products Administration on April 7 of this year and registered as an API intended for use in marketed formulations. The recent approval of tedizolid phosphate injection (200 mg) will play a positive role in the group’s further advancement of its “API + Formulation” strategy.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license